Levofloxacin is a synthetic broad-spectrum antibacterial agent for oral or intravenous administration. Chemically, levofloxacin is\nthe levorotatory isomer (L-isomer) of racemate ofloxacin, a fluoroquinolone antibacterial agent. Quinolone derivatives rapidly and\nspecifically inhibit the synthesis of bacterial DNA. Levofloxacin has in vitro activity against a broad range of aerobic and anaerobic\nGram-positive and Gram-negative bacteria. However, formulation of combined poloxamers thermoregulated (as Pluronic F127)\nand levofloxacin for use in multiresistant bacterial treatment were poorly described in the current literature.Thus, the aim of the\npresent work is to characterize poloxamers for levofloxacin controlled release and their use in the treatment of multidrug bacterial\nresistance.Micelles were produced in colloidal dispersions, with a diameter between 5 and 100 nm, which formspontaneously from\namphiphilic molecules under certain conditions as concentration and temperature. Encapsulation of levofloxacin into nanospheres\nshowed efficiency and enhancement of antimicrobial activity against Escherichia coli, Pseudomonas aeruginosa, and Klebsiella\npneumoniae when compared with only levofloxacin. Furthermore, all formulations were not cytotoxic for NIH/3T3 cell lineage.\nIn conclusion, poloxamers combined with levofloxacin have shown promising results, better than alone, decreasing the minimal\ninhibitory concentration of the studied bacterialmultiresistance strains. In the future, this new formulation will be used after being\ntested in animal models in patients with resistant bacterial strains.
Loading....